Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:9
|
作者
Chen ZhenPing [1 ]
Li PeiJing [1 ]
Li Gang [1 ]
Tang Ling [1 ]
Zhen YingZi [1 ]
Wu XinYi [1 ]
Cheng XiaoLing [1 ]
Hung Luke Koon [2 ]
Blanchette Victor S [3 ]
Poon ManChiu [4 ]
Ding QiuLan [5 ]
Wu RunHui
机构
[1] Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing 100045, China
[2] Department of Medicine, Pediatrics and Oncology, and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary, Foothills Hospital and Calgary Health Region, Calgary, Alberta, T2N2T9, Canada
[3] Department of Pediatrics and Laboratory Medicine, and Hemophilia Clinic, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, Ontario, K1H 8L1, Canada
[4] Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
[5] Department of Pediatrics and Child Health Evaluative Sciences, Division of Hematology/Oncology, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics;
D O I
暂无
中图分类号
R554.1 [];
学科分类号
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China.Methods: A total of 36 boys (plasma-derived [pd]-FVIII,n = 15; recombinant [r] FVIII,n = 21) were enrolled between January 2015 and May 2016 in Beijing Children’s Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion).Results: The mean FVIII half-life (t1/2) was 10.99 ± 3 .45 h (range 5.52- 20.02 h), the meanin vivo recovery (IVR) was 2.01 ± 0.42 IU/dl per IU/kg (range 1.24–3.02 IU/dl per IU/kg) and mean clearance (CL) of FVIII is 4.34 ± 1.58 ml·kg?1·h?1 (range 2.29–7.90 ml·kg?1·h?1). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R2 = 0.32,P< 0.01). The t1/2 of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF:Ag) also was associated with FVIII half-life (R2 = 0.52,P< 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 ± 0.68 h vs. 12.3 ± 0.79 h,t = 2.70,P= 0.01). The FVIII IVR correlated with age (R2 = 0.21,P< 0.01) and VWF:Ag level (R2 = 0.28,P< 0.01). CL rates were faster in young patients and in those with low-VWF:Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 ± 0.38 vs. 4.00 ± 0.32 ml·kg?1·h?1,t= 2.53,P= 0.02).Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF:Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1780 / 1785
页数:6
相关论文
共 50 条
  • [31] Joint status and related risk factors in patients with severe hemophilia A: a single-center cross-sectional study
    Zhao, Liang
    Yang, Hongbin
    Li, Yaochun
    Wang, Zhongqing
    Zhou, Li
    Zhao, Xielan
    Peng, Jie
    HEMATOLOGY, 2022, 27 (01) : 80 - 87
  • [32] Inversions of the factor VIII gene in Japanese patients with severe hemophilia A
    Fukuda, K
    Naka, H
    Morichika, S
    Shibata, M
    Tanaka, I
    Shima, M
    Yoshioka, A
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 79 (03) : 303 - 306
  • [33] Factor VIII inhibitors in patients with non-severe hemophilia
    Kempton, C. L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 78 - 79
  • [34] Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
    Megias Vericat, J. E.
    Marques, R.
    Haya, S.
    Cid, A. R.
    Querol, F.
    Monte, E.
    Garcias Dasi, M.
    Caunedo, P.
    Bosch, P.
    Curats, R.
    Poveda, J. L.
    Bonanad, S.
    HAEMOPHILIA, 2018, 24 : 92 - 93
  • [35] The factor VIII treatment history of non-severe hemophilia A
    Abdi, Amal
    Kloosterman, Fabienne R.
    Eckhardt, Corien L.
    Male, Christoph
    Castaman, Giancarlo
    Fischer, Kathelijn
    Beckers, Erik A. M.
    Kruip, Marieke J. H. A.
    Peerlinck, Kathelijne
    Mancuso, Maria Elisa
    Santoro, Cristina
    Hay, Charles R.
    Platokouki, Helen
    van Der Bom, Johanna G.
    Gouw, Samantha C.
    Fijnvandraat, Karin
    Hart, Dan P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (12) : 3203 - 3210
  • [36] INVERSIONS OF THE FACTOR-VIII GENE IN SEVERE HEMOPHILIA-A
    VANDEWATER, NS
    WILLIAMS, R
    NELSON, J
    BROWETT, PJ
    BLOOD, 1994, 84 (10) : A62 - A62
  • [37] Inversions of the Factor VIII Gene in Japanese Patients with Severe Hemophilia A
    Kazuyoshi Fukuda
    Hiroyuki Naka
    Shogo Morichika
    Masaru Shibata
    Ichiro Tanaka
    Midori Shima
    Akira Yoshioka
    International Journal of Hematology, 2004, 79 : 303 - 306
  • [38] FACTOR-VIII GENE REARRANGEMENTS IN SEVERE HEMOPHILIA-A
    BOWEN, DJ
    DAVIES, SV
    BLOOD, 1995, 85 (01) : 291 - 291
  • [39] Radiosynovectomy in children with severe hemophilia and factor VIII or IX inhibitor
    Laguna, P.
    Zbikowski, P.
    Cwikla, J.
    Klukowska, A.
    Matysiak, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 526 - 526
  • [40] DOMICILIARY DESENSITIZATION THERAPY FOR YOUNG BOYS WITH HEMOPHILIA AND FACTOR-VIII INHIBITORS
    LILLEYMAN, JS
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (02) : 433 - 435